Effect of dalcetrapib on non-cholesterol sterol markers of cholesterol absorption in patients with familial hypoalphalipoproteinaemia or familial combined hyperlipidaemia.
Phase of Trial: Phase II
Latest Information Update: 31 Aug 2012
At a glance
- Drugs Dalcetrapib (Primary)
- Indications Hyperlipoproteinaemia type IIb; Tangier disease
- Focus Biomarker; Pharmacodynamics
- Sponsors Roche
- 31 Aug 2012 New trial record
- 29 Aug 2012 Results presented at the Annual Congress of the European Society of Cardiology 2012 (ESC Congress 2012).